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Abstract Double pituitary adenomas are very rare and pres-
ent up to 1 % of pituitary adenomas in unselected autopsy
series and up to 2 % in large surgical series. We report a case
of a 47-year-old man presented slight clinical features of
acromegaly with 2 years duration. Endocrine evaluation
confirmed active acromegaly and revealed adrenocortico-
tropin hormone-dependent hypercortisolemia. Preoperative
magnetic resonance imaging of the pituitary demonstrated
clearly separated double microadenomas with different
intensity. The patient underwent transsphenoidal surgery
and both tumors were completely removed and were fixed
separately. The histological and ultrastructural examination
confirmed coincidence of the double, clearly separated
pituitary adenomas in one gland. Postoperative function
of the hypothalamo-hypophyseal axis was normalized.
We conclude from this case and a literature review that
double endocrinologically active pituitary adenomas lead-
ing to acromegaly and Cushing’s disease may occur.
Additionally, a review of the literature regarding multiple
pituitary adenomas has also been performed.
Keywords Double pituitary adenoma . Acromegaly .
Cushing’s disease . Immunohistochemistry . Electron
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Introduction
Pituitary adenomas are usually benign epithelial tumors aris-
ing from and consisting of adenohypophyseal cells. They are
most often slow growing, expansive tumors, confined to the
sella turcica [1]. Pituitary adenomas can be diagnosed in every
age group, but they are rarely found in prepubertal age. They
comprise approximately 10–15 % of all intracranial tumors
and cause typical clinical syndromes attributed to
overproduction or insufficient secretion of hypophyseal hor-
mones and/or local mass effects [2]. The vast majority of
pituitary adenomas are monoclonal tumors which have hor-
mone immunoreactivity and ultrastructural features of known
adenohypophysial cell types [3]. Among them are
plurihormonal tumors capable of producing two or more
hormones that differ in immunoreactivity and biological ef-
fects [4, 5]. Exeptionally, truly multiple pituitary adenomas
are recognized [6]. Authors present a case of double, clearly
separated pituitary adenoma with different histological fea-
tures causing Cushing’s disease and acromegaly. Both tumors
were recognized on preoperative MR imaging.
Case Report
A 47-year-old male was admitted to the Neurosurgical
Department with typical clinical features of acromegaly
(enlarged doughy hands and feet, frontal bossing, coarsen-
ing of facial features with increased interdental spacing and
prognathism, thickened lips, etc.) with 2 years duration. On
admission to hospital, clinical examination showed oily
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skin, weight gain with central fat distribution, slight purple
striae on the abdomen, and spontaneous ecchymosis.
Patient’s body weight was 117 kg and gained over 20 kg
per last year. His height was 181 cm and body mass index
(BMI) was 35.7 kg/m2. Observed central obesity was not
typically cushingoid without moon face and buffalo hump.
Patient’s main complaints were progressive headaches,
lowered mood, and decreased libido. His blood pressure
was slightly elevated and controlled with antihypertensive
drugs (selective beta blocker, ACE inhibitor and diuretic);
measured in supine position was 130/90 mmHg. His pulse
rate was 64 beats per minute. Neurological examination
revealed no impairment of visual acuity and visual fields
and intact function of other cranial nerves. Fundoscopic
examination showed no optic nerve atrophy. The patient
had neither family history of pituitary adenoma nor multiple
endocrine neoplasia. Endocrine investigation revealed
slightly elevated basal serum level of growth hormone
(GH) and somatomedin-C (insulin-like growth factor-1)
with abnormal oral glucose tolerance test (OGTT) and ab-
normal circadian rhythm of adrenocorticotropin hormone
(ACTH) and cortisol (Table 1). The high dose dexametha-
sone suppression test (8 mg) markedly reduced the concen-
tration of ACTH, cortisol, and its metabolites (17-OHCS
and 17-KS) although this effect was not observed with low
dose (1 mg) of dexamethason. Serum levels of GH and
thyroid-stimulating hormone (TSH) were increased in re-
sponse to an intravenous administration of thyrotropin-
releasing hormone, as shown in Table 2. The preoperative
serum prolactin (PRL) level was within normal limits—15.
1 ng/ml. Other pituitary hormones including TSH and go-
nadotrophins (follicle-stimulating hormone (FSH) and
luteinizing hormone (LH)) were also within normal ranges.
Intravenous administration of LH-RH caused increased se-
cretion of LH, FSH, and PRL (Table 2). Serum level of
testosterone was low but within normal limits. The function
of the thyroid gland was normal and intact parathyroid
hormone concentration was normal. Plain skull X-ray film
showed slightly enlarged pituitary fossa with thickening of
its floor without destruction of the dorsum sellae. Initial MR
imaging of the sellar region (coronal and sagittal T1-
weighted before Gd-DTPA administration) demonstrated a
slightly enlarged and asymmetrical pituitary gland (Ryc 1).
Coronal T1-weighted scan after administration of the contrast
medium revealed a nonhomogenic region on the right side of
the pituitary gland and a hypointensive area on its left side.
Coronal T2-weighted MR visualized a hyperintensive signal
of the smaller microadenoma on the right side, close to the
right cavernous sinus, and a nonhomogenic region on the left
side. Preoperative MR imaging suggested the presence of two
different tumors in the sella. Both of them are intrasellar
microadenomas without cavernous sinus invasion (Fig. 1).
Both, endocrine investigation and neuroimaging of the
pituitary gland strongly indicated coincidence of two differ-
ent (double) pituitary tumors causing acromegaly and
Cushing’s disease. No additional invasive diagnostic pro-
cedures (bilateral inferior petrosal sinus or cavernous sinus
sampling) were performed.
The patient underwent transsphenoidal operation. During
the surgery, the sella was exposed and the H-shaped incision
of the dura was made. The dura mater was opened and
separated from the pituitary capsule to expose the entire
anterior surface of the pituitary. Then the gland was carefully
explored, regardless of MRI findings. Preoperative suggestion
Table 1 Preoperative hormonal test values
Measured value Reference range
GH 5.42 µg/l <5 µg/l
IGF- I 608 µg/l 180–325 µg/l
ACTH 68.8 pg/ml 66.4 pg/ml <60 pg/ml
kortyzol 20.7 µg/dl 16.2 µg/dl 7–25 µg/dl
24-HourUFC 197 ng/24h….213 ng/24h 13.8–75.3 ng/24h
LDDST 8.86 µg/dl
HDDST–kortyzol 20.7 µg/dl 4.2 2.48
HDDST–17-OHCS 21.1 mg/d 11.2 5.7
HDDST–17-KS 30.2 mg/d 15.9 10.8
TSH 1.01 mIU/ml 0.3–3.5 mIU/ml
fT4 1.49 ng/dl 0.8–2.0 ng/dl
LH 1.12 mIU/ml 0.8–7.6 mIU/ml
FSH 5.01 mIU/ml 0.7–11.1 mIU/ml
PRL 15.1 ng/ml…MTC 60′…30.2 ng/ml <20 ng/ml
Testosteron 278 ng/ml 262–1,593 ng/ml
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about the presence of two different, clearly separated tumors
was confirmed. The mass on the left side of the sella was
yellowish, fibrous, and compact and that on the right side was
creamy, soft, and brittle. Both tumors were separated by
normal pituitary tissue. Excised lesions were fixed separately
for further histological examination.
Pathomorphological Methods
Material was fixed in 10 % formalin, embedded in paraffin,
and routinely stained with hematoxylin and eosin (H&E).
Immunohistochemical staining was performed on paraffin-
embedded specimens according to the labeled EnVision
Flex Visualization System (Dako, K8000) with DAB as
chromogen using antibodies against anterior pituitary hor-
mones or subunits: prolactin (PRL, dilution 1:200), growth
hormone (GH, dilution 1:500), ACTH (dilution 1:500), β-
TSH (dilution 1:200), β-FSH (dilution 1:500), β-LH (dilu-
tion 1:200)—all antibodies from Neo Markers; the glyco-
protein α-subunit (dilution 1:100, Novocastra); somatostatin
receptors: sstr2A and sstr5 (dilution 1:1500, BioTrend) and
Ki-67 (MIB1 clone)—from Dako. MIB-1 labeling index
was established.
For electron microscopy, small pieces of tissue were
fixed in 2.5 % cold glutaraldehyde, washed in cacodylate
buffer, postfixed in 1 % osmium tetroxide, dehydrated in a
graded series of ethanol, and embedded in Epon 812.
Ultrathin sections were counterstained with uranyl acetate
and lead citrate and examined with a Philips CM120
BioTWIN electron microscope (Fig. 2).
Results
Histology, Immunohistochemistry, and Ultrastructure
The pathological examination revealed two separate pitui-
tary adenomas showing different histological, immunohis-
tochemical, and ultrastructural features.
At light microscopy, the tumor removed from the left side
of the sella was insignificantly acidophilic, with a diffuse
pattern. The cells were slightly pleomorphic, medium-sized,
and partly angular. The round to oval nuclei showed mild
nuclear atypia, single nucleoli, and moderate heterochroma-
tin. Mitoses were very rare and <1 % of nuclei were MIB1-
positive. Immunohistochemistry demonstrated strong and
diffuse cytoplasmic positivity for GH, a scant positive
staining for PRL and immunopositivity for α-subunit in
>20 % of cells. This tumor was immunonegative for
ACTH, TSH, FSH, and LH. Tumor cells were strongly
immunopositive at the cell membranes for somatostatin
receptor sstr2A and weakly, cytoplasmic positive for sstr5.
Ultrastructural examination confirmed presence of densely
granulated somatotroph (GH cell) adenoma. The rough en-
doplasmic reticulum and the Golgi apparatus were moder-
ately developed. Cells had relatively increased number of
irregular mitochondria, scattered enlarged endosomes, and
Table 2 Hormone loading test results
0 Min 30 Min 60 Min
LHRH test
LH (mIU/ml) 1.12 10.9 9.54
FSH (mIU/ml) 5.01 8.77 9.87
TRH test
GH (ng/ml) 3.6 4.32 4.17
PRL (ng/ml) 11.8 24.6 22.3
TSH (mIU/ml) 1.5 7.26 6.22
Fig. 1 MR imaging of the sellar region demonstrated a slightly en-
larged and asymmetrical pituitary gland. a Coronal T1-weighted after
Gd-DTPA administration—a nonhomogenic region on the right side of
the pituitary gland and a hypointensive area on its left side near the
sellar floor. b Coronal T2-weighted—a hyperintensive signal of the
smaller microadenoma on the right side, close to the right cavernous
sinus and a nonhomogenic region on the left side
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numerous spherical lysosomes. Medium-sized (250–450 nm),
round to oval secretory granules withmedium electron density
were very numerous. Secretory granules were often noticed in
cytoplasmic processes (Fig. 3).
The other tumor at the right side of the sella was basophilic
adenoma with cellular pleomorphism. Histologicaly this tu-
mor consisted of oval to polygonal cells with pleomorphic
nuclei and often multiple nucleoli. The cells were mainly
arranged in a diffused and partly palisading, or sinusoidal
growth pattern. Mitotic figures were very rare and the Ki-67
nuclear labeling index (clone MIB-1) was <1 %.
Immunohistochemistry demonstrated plurihormonal adenoma
with intense cytoplasmic staining for ACTH. A moderate
number of LH- and α-subunit-positive cells (>30 %) were
detected in a scattered distribution. The remaining adenohy-
pophysial hormones were immunonegative.
Ultrastructural examination revealed presence of mono-
morphic, sparsesely granulated corticototroph pituitary ade-
noma. This adenoma was composed of cells that had oval or
angular morphology with irregular nuclei containing large
conspicuous nucleoli. The rough endoplasmic reticulum and
Golgi were well developed but slightly irregular. Some cells
exhibited enlarged mitochondria with disrupted cristae and
scattered enlarged lysosomes. The secretory granules were
pleomorphic in shape and tended to accumulate along the
cell membrane. Two kinds of granules were revealed: (1)
pleomorphic, high electron dense, measuring 200–450 nm
in size and (2) round and small (about 150 nm in diameter),
with lower electron density. No bundling of intermediate
filaments was observed.
Clinical Results
The postoperative course was uneventful. Early morning post-
operative serum cortisol level, measured on the first day after
surgery, was below 1 μg/dl. Typical replacement therapy with
intravenous hydrocortisone was started and then the standard
dose: 20 mg in the morning and 10 mg at 3.00 p.m. p.o. was
administered and continued until the next hormonal evalua-
tion. There were no diabetes insipidus and any water electro-
lyte disturbance, especially hyponatremia. Patient was
discharged from neurosurgical department on the fourth post-
operative day and transferred to the endocrinological outpa-
tient clinic.
Postoperative (3 months after surgery) serum GH level
was 0.791 μg/l and the OGTT was below 0.4 μg/l. The
serum IGF-I level was 120 μg/l (within normal age- and
Fig. 2 Immunohistochemistry
in the somatotroph tumor (left
side of the sella). Positive
staining for: GH (a), PRL (b)
and α subunit (c), and negative
for ACTH (d). Original
magnification, ×200
Fig. 3 Ultrastructure of densely granulated somatotroph adenoma.
Original magnification, ×9,700
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sex-related range; Table 3). Postoperative serum (1.3 μg/dl)
and urinary (12.8 μg/24 h) cortisol levels were low, as well.
The patient was on hydrocortisone replacement therapy for
at least 18 months. After that time, regular function of the
pituitary–adrenal axis was restored and replacement therapy
was withdrawn. During the overnight oral 1-mg dexameth-
asone suppression test, serum cortisol level was suppressed
below 1.8 μg/dl. During follow-up, patient’s thyroid func-
tion was normal. There were no hypogonadism. His serum
levels of gonadotropins (FSH and LH) were within normal
range. Postoperative PRL serum level was also normal
(PRL, 8.74 ng/ml). There were no remnants of the tumors
on the postoperative MR scans carried out after 6 months.
Laboratory evaluation carried out 4 years after surgery
confirmed normal pituitary function. There were no
hypocorticoidism, hypothyroidism, and hypogonadism.
During the follow-up period (6 years), the patient’s pituitary
function has been normal and we have not observed pitui-
tary adenomas regrowth on the MR imaging (Fig. 4).
Discussion
Multiple pituitary adenomas are defined as two or more
simultaneous adenomas with distinct light microscopic and
immunohistochemical features in a single gland [6]. They
are classified as clearly separated tumors visible at preoper-
ative imaging or during surgical exploration and contiguous
adenomas which might be recognized only by pathologist
[7]. From the clinical point of view, it should be stress that
multiple pituitary lesions are very rare. These tumors usually
are microadenomas and most of them are clinically silent.
Their incidence was evaluated at 0.9–1 % in unselected
autopsy series [1, 8]. Kontogeorgos et al. identified 20 (4.
26 %) cases of multiple adenomas in 470 pituitary autopsies
[8]. Buurman and Seager found multiple adenomas in 17 (5.
4 %) out of 316 studied autopsies [9]. Surgical case reports
presented their rate at 0.2–1.8 % [10–12]. Kontogeorgos et
al. in a study of 3,000 surgically removed pituitary tumors
reported 11 cases (0.36 %) synchronous detected of more
than one pituitary adenoma in one gland [6].
Most of the presented multiple adenomas were found in
acromegalic patients. Kontogeorgos et al. have noted seven
GH-secreting pituitary tumors out of 12 cases of double
pituitary adenomas [6, 8]. Another six cases have been
described by Sano et al. [11]. The majority of double
Table 3 Postoperative hormonal values
Endocrinological evaluation three months after
surgery
GH 0.791 ng/ml
OGTT 30′ 60′ 90′ 120′
1.23 0.356 0.065 0.246
ACTH 12.0 pg/ml 1.03 pg/ml
kortyzol 3.3 μg/dl 1.37 μg/dl








in the corticototroph tumor
(right side of the sella). Positive
staining for: ACTH (a), LH (b),
and α subunit (c), and negative
for GH (d). Original
magnification, ×200
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adenomas were composed of somatotropinoma and
prolactin-secreting or nonfunctioning adenomas [10, 13,
14].
However, one should remember that multiple adenomas
might occur at increased frequency in patients with
Cushing’s disease, as well. A study by Ratliff and Oldfield
found double pituitary adenomas in 13 of 660 operated
patients, 11 of which were detected in patients with
Cushing’s disease [12]. Meij et al. reported three cases of
double pituitary lesions in patients with Cushing’s disease
[15]. Two out of three patients harboring double pituitary
tumors reported by McKelvie presented ACTH-dependant
hypercortisolemia [16]. Rotondo and coworkers presented
very interesting and rare case of double, separate adenomas
with different histological and immunohistochemical fea-
tures, one of which demonstrating immunopositivity for
ACTH and the second for LH and alpha subunit [17].
There is only one known case of double clearly separated
pituitary adenomas both secreting ACTH [7]. The most
common incidental lesions coexisting with ACTH-
secreting adenoma were prolactinomas [12].
Multiple pituitary adenomas ordinarily occur simulta-
neously. Thodou at al. presented a metachronous double ade-
nomas which have been occurred in the same patient [18].
The pathogenesis of multiple pituitary adenomas remains
unknown [10, 17]. In normal pituitary gland, pluripotent
progenitor cell differentiates into three different lineages
that produce POMC (ACTH), FSH-LH, and GH-PRL-TSH
[19]. Several genetic abnormalities (e.g., mutation of Gs
protein) might be involved in their transformation
(oncogenesis) to the hyperplastic or adenomatous cells
[20]. Autocrine/paracrine interactions may participate in
the mechanisms underlying the development of the adeno-
ma [10]. Altered hypothalamic function may play a role in
pituitary tumorigenesis, as well [1, 2, 21]. Multiple adeno-
mas may also be the result of the incidental occurrence of
two or more monoclonal pituitary tumors [10]. Further
molecular studies are indispensable to explain the pathogen-
esis of multiple pituitary adenomas and mechanisms of their
multidirectional phenotypic differentiation.
There is not much information about detection of the
multiple pituitary adenomas on preoperative MR images
[12]. It is well known that the precise preoperative MR
localization of a pituitary microadenoma is associated with
greater efficacy of operative treatment and lack of such
localization might be associate with surgical failure, espe-
cially in Cushing’s disease and multiple pituitary tumors
[22]. The identification of pituitary microadenomas is diffi-
cult because the diameter of some tumors is usually below
MRI resolution [8, 12, 15]. Modern MR imaging offers
greater sensitivity in the detection of pituitary tumors.
Dynamic MR imaging is considered to improve detection
of minute pituitary adenoma, but Tabarin et al. reported no
significant differences between diagnostic accuracy of stan-
dard and dynamic MRI techniques [23]. Patronas et al.
presented superior sensitivity and diagnostic accuracy of the
spoiled gradient recalled acquisition in the steady state MRI
technique compared with the spin echo (SE)MRI technique in
the detection of the corticotroph microadenomas (80 vs.49 %)
[24]. Ikeda et al. have recently confirmed a usefulness of the
MET-PET/3.0-T MR imaging in the detection of ACTH-
secreting pituitary adenomas and its higher sensitivity than
other neuroradiological imaging techniques such as MR im-
aging, dynamic MR imaging, and CT scanning [25]. Stobo et
al. have proved the applicability of 3.0 T MRI for detection of
hormonally active pituitary microadenomas not visible in 1.
5 T MR imaging lately [26].
We detected both tumors on preoperative scanning using
high-resolution 1.5 T MRI, T2-weighted, pre- and
postcontrast T1-weighted SE technique. In those cases, in
Fig. 5 Electron microscopy image of plurihormonal/corticotroph ade-
noma. a Low power view of polygonal cells with irregular nuclei and
well developed organelles. Original magnification, ×4,700. b Higher
magnification: variability in the size and electron density of granules.
Original magnification, ×24,500
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which pituitary lesion is not precisely localized, intraoperative
ultrasonography seems to be useful for demonstration the
presence of minute adenomas or simultaneous double or mul-
tiple pituitary tumors and therefore might improve the efficacy
of transsphenoidal surgery. Watson et al. reported the useful-
ness of this technique for the visualization of the pituitary
microadenomas that are not evident on preoperativeMR scans
in patients with Cushing’s disease [27]. Arita and coworkers
found this technique capable for demonstration entire pituitary
gland and its tumor, pituitary stalk, optic chiasm, and cavern-
ous sinus invasion in patients with small adenomas [28].
In our material of more than 2,600 cases of surgically treated
pituitary tumors, we recognized six “double simultaneously
coexisting pituitary adenomas”. Herein, we present clinical data
on a case of unusual double microadenomas which were recog-
nized and precisely localized on preoperative MR imaging and
were confirmed during surgery and on histological examination.
In our case, both tumors were clinically active. The signs
and symptoms of acromegaly and Cushing’s disease occurred
simultaneously but somatic features of acromegaly were rec-
ognized earlier. ACTH-dependant hypercortisolemia was con-
firmed preoperatively by scrupulous laboratory investigation.
The diagnosis was based on biochemical evidence and preop-
erative endocrinological testing according to current guidelines
[29, 30]. Initial MR imaging showed two distinct pituitary
microadenomas. Both endocrine investigation and neuroimag-
ing of the pituitary gland strongly indicated coincidence of two
different (double) pituitary tumors causing acromegaly and
Cushing’s disease and therefore no additional invasive diag-
nostic procedures (bilateral inferior petrosal sinus or cavernous
sinus sampling) were performed. Our suspicion was confirmed
during surgery and pathological examination.
Plurihormonality is rarely seen in corticotroph and
gonadotroph adenomas [31]. Ikeda et al. suggested that
gonadotroph adenomas occasionally produce ACTH in
amounts capable of inducing Cushing’s disease [32]. We
demonstrated in the tumor removed from the right side of
the sella the ultrastructurally confirmed sparsely granulated
corticotroph adenoma with immunohistochemical evidence
of LH and alpha subunit. Monomorphic cells contained two
types of granules: polymorphic with high electron density,
resembled those of normal corticotrophs and round, smaller,
with lower electron density granules (Fig. 5).
The first published case of two synchronous pituitary adeno-
mas causing Cushing’s disease and acromegalywas presented by
Blevins et al. [33]. However, coexistence of Cushing’s disease
and acromegaly has been reported in several another patients
harboring pituitary adenomas with concomitant secretion of GH
and ACTH [34–36]. Furthermore, it should be stressed that co-
occurrence of acromegaly and hypercortisolemia might be a
consequence of coexistence of the GH-secreting pituitary adeno-
ma and adrenal tumor/nodular adrenal hyperplasia or ACTH-
secreting bronchial carcinoid [37–39]. Those extremely rare
coincidences are very important from the surgical point of view
and responsible for treatment failure [11, 12, 14, 40, 41]. They
could be an unusual cause of failure of medical therapy for PRL-
secreting pituitary adenoma, as well [42].
Conclusions
1. Scrupulous preoperative endocrinological examination
has to be performed in every case of pituitary adenoma,
especially functioning tumors.
2. Precised evaluation of preoperative MR imaging is
mandatory in every case of pituitary lesion.
3. Extensive surgical exploration of the sella has to be
thorough in order to avoid surgical failures.
4. Histopathological examination of the removed tissue
according WHO recommendation should be mandatory.
The immunohistochemical methods and/or ultrastruc-
tural analysis are required to confirm an exact diagnosis
of the multiple pituitary adenomas.
5. Scrupulous follow-up is recommended for all patients
after successful surgical removal of hormonally active
pituitary tumors. It plays an important role in confirma-
tion the diagnosis and further observation to distinguish
“cured patients” from those with “apparent remission”
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